You are likely correct with your numbers for US CLIA initially. I do think it will be on the higher end of your range. Good partner, data, and reimbursement could push it higher. Lots of clinical trials that would start up because of this test. In the very near future, 2015-16, we will be talking about ex-US sales too I believe. A really strong partner can have a big price effect too. However, your numbers are likely a reasonable range.